Title |
Negotiating excess treatment costs in a clinical research trial: the good, the bad and the innovative
|
---|---|
Published in |
Trials, February 2016
|
DOI | 10.1186/s13063-016-1208-5 |
Pubmed ID | |
Authors |
Rebecca Palmer, Madeleine Harrison, Elizabeth Cross, Pam Enderby |
Abstract |
Barriers to recovering the excess treatment costs associated with health research from local organisations in the United Kingdom can increase research costs, delay completion of high- quality studies and risk disenfranchising health trusts and patients from participation. The authors demonstrate how the process for recovering excess treatment costs at a local National Health Service (NHS) trust level in a multicentre study was inconsistent and resulted in excess effort and cost to the research budget. An innovative example of how an organisation acting as a broker between commissioners and researchers facilitated a more timely excess treatment cost agreement is highlighted. Current Controlled Trials ISRCTN68798818 , registered on 18 February 2014. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 4 | 44% |
Unknown | 5 | 56% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 56% |
Scientists | 2 | 22% |
Practitioners (doctors, other healthcare professionals) | 2 | 22% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 32% |
Student > Master | 4 | 21% |
Student > Bachelor | 4 | 21% |
Student > Ph. D. Student | 1 | 5% |
Unknown | 4 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 21% |
Nursing and Health Professions | 4 | 21% |
Business, Management and Accounting | 2 | 11% |
Agricultural and Biological Sciences | 2 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Other | 2 | 11% |
Unknown | 4 | 21% |